Patent Application
20120191027
1. Technical Field
The invention pertains to bioresorbable barbs and spikes designed to affix biologically-active blood plasma-derived plastics adjacent to injured tissue for wound coverings, patient implantation devices, or in other medical applications where such affixation is required.
2. Background Information
Platelet-rich Plasma (PRP) spun from a patient's own blood has been used since the mid-1980s as a way to accelerate tissue healing. Chronic skin wounds are particularly difficult to treat, and non-healing ulcers are the most frequent cause for amputation. For example, diabetic foot ulcers (DFU) pose a major world-wide health problem due to the associated complications of recurrence, chronicity and amputations. In 2004 in the U.S. there were approximately 71,000 non-traumatic lower-limb amputations in people with diabetes with a cost per patient ranging from $20,000 to $60,000 per case. There has been a dramatic global increase in the prevalence of diabetes mellitus, particularly type II diabetes, which has a lifetime risk of a diabetic patient developing a foot ulcer approaching 25%.
Described herein are barbs or spikes manufactured from blood plasma-derived plastics for fixating tissue with a biologically compatible material that encourages tissue healing. The barbs can be formed on blood plasma-derived plastic articles such that the barbs affix the article to injured or repaired tissues. In some embodiments, the barbs are positioned and spaced on a blood plasma-derived plastic such that the barbs are optimally situated. For example, the barbs can be positioned across one face of the scaffold. In some embodiments, the barbs can be positioned along one edge on one face of the scaffold. In some embodiments, the barbs can be positioned around the periphery of one face of the scaffold.
Also provided herein are methods of manufacturing barbs from blood-plasma-derived plastics by molding and post-processing. For example, barbs can be prepared in blood plasma-derived plastic articles such that the plastic barbs have stronger mechanical properties than the blood plasma-derived plastic from which they are constructed. In some embodiments, barbs are prepared using blood plasma-derived plastics such that the barbs controllably swell in place, providing more secure fixation. In some embodiments, a means is provided for inserting molding barbed materials into blood plasma-derived plastic articles so as to take advantage of the strength of barbed materials made from different materials than the blood plasma-derived article.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
These and other features, aspects and advantages of the present teachings will become better understood with reference to the following description, examples and appended claims.
The plastic articles of the present invention are prepared from a composition comprising blood plasma, onto which fixation barbs are molded or insert molded into the articles to affix such articles adjacent to the tissues being treated.
As used herein, the term “plasma” is intended to mean blood plasma, including plasma containing no platelets (“platelet-poor plasma”), plasma containing platelets (“platelet-rich plasma”), or plasma where the platelets have been concentrated by spinning in a centrifuge (“platelet-enriched plasma”). Blood is a bodily fluid (technically a tissue) that is composed of blood cells suspended in a liquid called blood plasma. The blood cells present in blood are red blood cells (also called RBCs or erythrocytes) and white blood cells (including both leukocytes and lymphocytes). Also in blood are platelets (also called thrombocytes), which are cell fragments derived from the fragmentation of precursor megakaryocytes. Plasma makes up about 55% of blood by volume. Blood plasma is essentially an aqueous solution containing about 92% water, about 8% blood plasma proteins (such as serum albumin, blood clotting factors, immunoglobulins (antibodies)), various other proteins, various electrolytes, such as sodium and chloride, and trace amounts of other materials. Blood plasma as used as a component to prepare plastic articles of the present invention refers to the straw-colored liquid portion remaining after the material bodies such as blood cells and cell fragments are separated out from the blood.
Normal platelet counts in human blood average approximately 200,000/μL; PRP has a platelet concentration 3-5 times larger, with a threshold of 1,000,000/μL. PRP also contains multiple natural growth factors and other proteins that appear to accelerate tissue healing. PRP can deliver a concentration of natural growth and regenerative factors to a wound thereby initiating a robust healing cascade that can accelerate the healing of injured tissue. Because PRP can be made from autologous blood, it is relatively safe and free from transmissible diseases from other patients, such as HIV and hepatitis.
Platelets contain numerous growth factors that are released as the platelets are activated. The primary platelet-derived growth factors are: platelet derived growth factor (PDGF-AA, PDGF-BB, PDGF-AB) transforming growth factor beta (TGF-β1, TGF-β2), vascular endothelial growth factor (VEGF), and epithelial growth factor (EGF). These are native growth factors in their biologically correct ratios; this distinguishes PRP from recombinant growth factors. Recombinant growth factors are pure human growth factors, but they are not native growth factors. Instead they are synthesized usually by a culture of Chinese hamster ovarian cells that have a human gene inserted. Recombinant growth factors are single growth factors and are delivered in high doses. PRP is the combination of numerous native growth factors that act by stimulating, for example, cell growth (mitogenesis) and vascularin-growth (angiogenesis).
As used herein, the term “scaffold” is intended to mean either an elastomeric and flexible article that easily contours to the shape of tissue of underlying tissue to which it is positioned, or “scaffold” can mean a rigid plastic article that provides an impetus for encouraging cell growth and healing.
As used herein, the term “barb” is intended to mean a sharp projection with a point design that includes a bent portion (e.g., bent back upon itself, bent forward, bent sideways, or any combination thereof) or with a wedge shape that prevents easy extraction from tissue into which it is inserted. In some embodiments, a barb is less than about 5 mm in length and sufficiently small in diameter (typically less than about 2 mm) such that the insertion of the barb does not cause tissue trauma or undue pain.
As used herein, the term “spike” is intended to mean a sharp pointed projection that can easily be inserted into tissue. In some embodiments, a spike is less than about 5 mm in length and sufficiently small in diameter (typically less than about 2 mm) such that the insertion of the spike does not cause tissue trauma or undue pain.
As used herein, the terms “fixation,” “fixate,” and “affix” are intended to mean types of physical attachments including attachment with a barb such that the barb cannot be easily removed from the tissue; and attachment with a spike such that the spike prevents shear movement and prevents a spiked apparatus, for example, from sliding across a plane of tissue. Typically, a fixed apparatus containing spikes will not pull away from the tissue by pressure exerted by surrounding tissues.
The source of blood plasma used to prepare the articles of the present invention can include humans and other mammalian species, for example, primates, dogs, cats, rodents and livestock such as sheep, goats, pigs, horses, and cattle. Blood plasma can be pooled plasma from a number of different donors (“allogenic”) or can be from an autologous (single) source. As used herein, “allogenic” means that the plasma is taken from different individuals of the same species.
As used herein, “dough” is defined as the combination of plasma powder, plasticizer and any other components that are mixed prior to plasticization.
As used herein, the term “biocompatible” refers to the absence of stimulation of a severe, long-lived or escalating biological response to an implant, and is distinguished from a mild, transient inflammation which typically accompanies surgery or implantation of foreign objects into a living organism.
As used herein, “biological response modifier” means any protein, glycoprotein, polysaccharide, lipid, DNA, RNA, aptamer, peptide, hormone, vitamin and other such substance, which when introduced into a subject is capable of eliciting a biological response, and includes, but is not limited to, cytokines, growth factors, protein hormones, genes, or genetically modified organisms, such as viruses and bacteria, extracellular matrix molecules and the like. The biological response modifier(s) can be present in the blood plasma used to prepare the composition, or added to the composition as a separate component prior to formation of the article.
In some embodiments, the barbs or spikes comprise at least one crosslinking agent for crosslinking various cross-linkable groups of the blood plasma and/or other components of the composition. For example, genipin (Methyl (1R,2R,6S)-2-hydroxy-9-(hydroxymethyl)-3-oxabicyclo[4.3.0]nona-4,8-diene-5-carboxylate) can be used as a chemical cross-linker. The amount of crosslinking agent used in the composition can range from about 0.0 to about 0.25 weight percent, or about 0.0 to about 0.5 weight percent, or about 0.0 to about 1.0 weight percent, on a basis of total weight of the composition.
In some embodiments, the composition comprises at least one drug. The term “drug” refers to a substance used as a medication or in the preparation of a medication, including, but not limited to, a substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. For example, a drug may include, but is not limited to, small organic molecules, complex organic molecules, inorganic elements and molecules, and the like. As used herein, the term “drug” encompasses, for example, fungicides, anticoagulants, antibiotics, antivirals, anti-inflammatories, both steroidal and non-steroidal.
In some embodiments, the articles of the present invention are in the form of stacked or laminated layers of sheets prepared from a blood plasma-derived plastic. Thermal processing of blood-plasma derived plastics imparts additional mechanical strength to the material at the expense of destroying biological factors inherent within the processed blood plasma that direct cell proliferation, differentiation, migration, and function in the process of wound healing. By laminating blood plasma-derived plastics made at different temperatures, a scaffold product that contains a high proportion of inherent biological factors along with greater strength and/or barrier properties can be constructed. In some embodiments, the layers are made with greater amounts of cross-linking agents to provide the benefit of materials that degrade at different rates, providing a combination of longer lasting mechanical and physical properties with a longer and controlled release of growth factors. In some embodiments, the barbs or spikes may be formed in a laminated sheet. For example, the barbs or spikes can be formed at a layer with greater physical and mechanical properties.
Also provided herein are blood plasma-derived soft plastic scaffolds which can be used to enhance the healing of wounds, such as ulcerated (e.g., diabetic foot ulcers) or burned skin, tendon and ligament injuries, nerve damage, and muscular injuries.
Blood plasma-derived plastics can be created by lyophilizing blood plasma and creating a dough from the remaining powder by the addition of a plasticizer (e.g., glycerol) and optionally other components. See, for example, U.S. 2008/0286329; U.S. 2008/0111272; U.S. 2010/0254900; WO 2007/126411; and WO 2009/014776. The dough can be either compression molded or extruded into plastic articles. In some embodiments, spikes that are pre-formed into the plastic articles are incorporated during molding, and barbs are then formed in a post processing procedure. In some embodiments, barbs made of a harder and/or stronger biocompatible and bioresorbable material, for example, a formula of blood plasma-derived plastic different from that of the base article or a synthetic plastic such as poly(methyl methacrylate) (PMMA) or poly(lactic acid) (PLA), are insert molded into the article. In some embodiments, spikes are molded into the blood plasma-derived article. In some embodiments, spikes are made of a material capable of swelling as it hydrates, thereby fixating the article by such expansion. Non-limiting examples of materials capable of swelling upon hydration include certain blood-derived plastics and polysaccharides (e.g., cellulose).
Blood plasma-derived plastics can be made to swell as much as 40%. Typically, blood plasma-derived plastics are made using pressures of approximately 10,000 p.s.i. Swelling can be induced by the use of lower pressures, for example, about 3,000 to 10,000 p.s.i. Swelling can also be induced by the use of lower temperatures during processing, for example, temperatures less than about 100° C. In some embodiments, spikes are molded as the article is compression molded by providing cavities into which the material is forced. If these cavities are made so as to be open to their environment, the amount of pressure forming the spikes is appreciably less than the rest of the article, which induces preferential swelling of the spikes over the plastic article.
In some embodiments, a tissue attachment spike device incorporates barbs manufactured from blood plasma-derived plastics. These attachment spikes can be manufactured in single or multiple cavity molds.
Also provided herein are barbs made from a material other than a blood plasma-derived plastic. The barbs can be insert-molded into a blood plasma-derived plastic article. For example, a scaffold made from a blood plasma-derived plastic can be contoured around tissue due to its flexibility. In some embodiments, such a scaffold is used to wrap an injured tendon or nerve, or a scaffold might be positioned between a bone and tendon. In some embodiments, the scaffolds are flexible and elastomeric, properties that make it difficult to create effective barbed spikes from the same material as such barbs would be too soft to either penetrate tissue or retain the tissue. In some embodiments, barbs are constructed of a material that is different than the blood plasma-derived plastic scaffold. For example, such barbs can be constructed of different formulations of blood plasma-derived plastics. In some embodiments, the barbs include one or more cross-linking agents or additives, such as tri-calcium phosphate (TCP), that provide the plastics with hardness and additional strength. In some embodiments, the barbs are constructed of blood plasma-derived plastics that have been exposed to temperatures exceeding 100° C., thereby creating a blood plasma-derived plastic of greater strength and hardness. In some embodiments, the barbs are constructed of other biocompatible polymers, such as PMMA or PLA.
The barbed materials can be insert-molded into the scaffold.
The barbs can be positioned and spaced according to the intended application. For example, a wound covering might include barbs located at the periphery of a blood plasma-derived scaffold, as shown in
This application claims the benefit of priority of U.S. Provisional Application Ser. No. 61/436,412, having a filing date of Jan. 26, 2011, which is incorporated by reference herein in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 61436412 | Jan 2011 | US |
